Latest Lead News

Electro Optic Systems (EOS) has landed a US$22 million deal to supply Remote Weapon Systems for a major U.S. Army combat vehicle, marking a significant milestone in its U.S. market expansion. This contract boosts EOS’s contract backlog to over A$400 million, setting the stage for robust revenue growth in the coming years.

InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.

Perseus Mining has expanded and refinanced its corporate debt facility to US$400 million, significantly enhancing its liquidity position to over US$1.2 billion. This move positions the gold miner strongly for future growth and shareholder returns.

The Supreme Court of New South Wales has approved Southern Cross Media's acquisition of Seven West Media, setting the stage for a significant media industry consolidation early next year.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

American Tungsten & Antimony Ltd plans to unlock value by spinning out its Drummond Basin and NSW gold exploration assets into a new ASX-listed company, King Metals Limited, aiming to raise up to $6 million in an IPO.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Elevate Uranium has expanded its global uranium resource base to 169 million pounds of U3O8 through the strategic acquisition of the Napperby Uranium Project and complementary assets from Core Lithium. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.

Elevate Uranium Ltd has expanded its global uranium resource to 169 million pounds of U3O8 through the acquisition of the Napperby Uranium Project and complementary assets from Core Lithium Ltd. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.